Brief: Fate Therapeutics Reports Initiation Of Phase 1 Trial For FT825 / ONO-8250
08/01/2024 18:09
Jan 8 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL
TRIAL
FOR FT825 / ONO-8250 IN PATIENTS WITH HER2-EXPRESSING ADVANCED
SOLID TUMORS
Source text for Eikon: ID:nGNXbdKvPH
Further company coverage: FATE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview